Most-Favored-Nation Drug Pricing and Its Clinical Impact
Most-Favored-Nation (MFN) drug pricing sounds simple on paper: tie what the U.S. pays for certain drugs to the lowest price available in comparable countries. And the motivation is real. In 2022, U.S. prescription drug prices were 2.78× those in 33 other OECD countries; for brand-name drugs, U.S. prices were more than 3× higher. The U.S. […]